Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;4(6):818-824.
doi: 10.1016/j.euf.2017.02.016. Epub 2017 Mar 11.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort

Affiliations

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort

Jennifer Cullen et al. Eur Urol Focus. 2018 Dec.

Abstract

Background: ETS-related gene (ERG) oncogenic activation is the most common genomic alteration in prostate cancer (CaP) although it occurs less frequently in African American (AA) versus Caucasian (CA) patients, and the potential role of ERG as a prognostic marker has not been confirmed.

Objective: This study was conducted to confirm strong racial variation in the prevalence of ERG oncoprotein expression and to examine ERG oncoprotein expression, race, and body mass index as independent and joint predictors of CaP biochemical recurrence (BCR) following radical prostatectomy (RP).

Design, setting, and participants: A retrospective cohort study of CA and AA CaP patients enrolled at Walter Reed National Military Medical Center, who donated clinically annotated, whole-mounted, prostatectomy specimens between 1994 and 2014 following RP, was conducted.

Outcome measurements and statistical analysis: Kaplan-Meier (KM) estimation curves and multivariable Cox proportional hazards models were used to examine time to BCR as a function of ERG status, patient race, and obesity.

Results and limitations: Among 930 eligible patients (36.1% AA and 63.9% CA), with 155 (16.7%) BCR events and a median follow-up time of 5.1 yr, ERG oncoprotein expression was significantly less prevalent in index tumors of AA versus CA patients (23.2% vs 49.3%; p<0.0001). KM curves showed significantly poorer BCR-free survival for CA patients with ERG-negative index tumors but not for AA patients. Race-stratified multivariable analyses revealed a significant association between ERG-negative index tumors and poorer BCR-free survival among CA patients (hazards ratio=1.67, confidence interval=1.07, 2.61; p=0.024). Less heterogeneity in ERG expression among AA patients may reduce the ability to show its association with BCR.

Conclusions: Striking racial variation in ERG oncoprotein expression was confirmed. A novel observation was the importance of index tumor ERG-negative status in predicting CaP progression for CA patients.

Patient summary: ETS-related gene (ERG) typing of tumors may be useful in prognosticating prostate cancer aggressiveness.

Keywords: Biochemical recurrence; ERG fusion; Obesity; Prostate cancer; Race.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier estimation curve of time to BCR as a function of index tumor ERG status (negative vs positive) for CA patients (n = 594). For CA patients, the log-rank p value (p = 0.0160) indicates that there is a statistically significant relationship between ERG status and BCR. In such patients, an index tumor that is ERG negative (ie, not expressing the ERG oncoprotein) is predictive of greater odds of having a BCR event over time. BCR = biochemical recurrence; CA = Caucasian ERG = ETS-related gene.
Fig. 2
Fig. 2
Kaplan–Meier estimation curve of time to BCR as a function of index tumor ERG status (negative vs positive) for AA patients (n = 336). For AA patients, the log-rank p value (p = 0.9686) indicates that there no relationship between ERG status and BCR over time. AA = African American; BCR = biochemical recurrence; ERG = ETS-related gene.

Similar articles

Cited by

References

    1. American Cancer Society. Cancer facts & figures. Atlanta, GA: American Cancer Society; 2016.
    1. Farrell J, Young D, Chen Y, et al. Predominance of ERG-negative high-grade prostate cancers in African American men. Mol Clin Oncol. 2014;2:982–6. - PMC - PubMed
    1. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res. 2008;14:4719–25. - PubMed
    1. Khani F, Mosquera JM, Park K, et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res. 2014;20:4925–34. - PMC - PubMed
    1. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24:3847–52. - PubMed

Publication types

MeSH terms